Rein Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNTX Nasdaq 2836 www.reintx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rein Therapeutics Inc.

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - Jun 11th, 2026 6:00 am
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option - May 18th, 2026 6:00 am
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - Apr 30th, 2026 6:00 pm
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - Apr 29th, 2026 6:00 am
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - Mar 3rd, 2026 6:00 am
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis - Jan 20th, 2026 6:00 am
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF - Nov 6th, 2025 5:30 am
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Nov 3rd, 2025 5:30 am
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Oct 9th, 2025 5:30 am
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis - Sep 17th, 2025 5:30 am
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls - Aug 19th, 2025 7:32 am
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Aug 19th, 2025 6:00 am
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - Aug 14th, 2025 3:00 pm
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing - Jul 30th, 2025 6:30 am
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - Jun 24th, 2025 8:11 am